Alexion Issues 2016 Guidance - Quick Facts

(RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) announced on a non-GAAP and constant currency basis, for 2016, the company expects: total product revenues in the range of $3.17 to $3.22 billion; and earnings per share of $5.31 to $5.51.

Based on forecasted results at current spot rate net of hedging activities, for 2016, the company expects: total product revenues in the range of $3.05 to $3.10 billion; and earnings per share in the range of $5.00 to $5.20.

David Hallal, CEO of Alexion, said: "In 2016 we will continue to focus on serving an increasing number of patients with PNH and aHUS globally, executing on the global launches of Strensiq and Kanuma, and advancing our complement and metabolic pipeline programs to drive our future growth. We look forward to reporting on multiple milestones in our expanding development pipeline in 2016, including results from two registration trials, and our broad and innovative mid-stage development programs."